Xanthine Oxidase Inhibitor Overdose (Allopurinol Toxicity)

Overview

Xanthine oxidase inhibitors are a class of drugs that reduce the production of uric acid. The most widely used agent is allopurinol, prescribed for gout, recurrent kidney stones, and for prevention of tumor‑lysis syndrome in oncology patients. An overdose or toxicity occurs when the amount taken exceeds the therapeutic dose, either accidentally (e.g., medication error) or intentionally (suicide attempt). Toxic levels can lead to severe metabolic disturbances, renal failure, and life‑threatening skin reactions.

Although true overdose is relatively uncommon, the drug’s widespread use means that clinicians encounter toxicity regularly. Estimates suggest that allopurinol‑related adverse events account for 5–10 % of drug‑induced severe cutaneous adverse reactions (SCARs) such as Stevens‑Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In the United States, ≈1–2 % of patients on allopurinol experience serious toxicity, with higher rates in those with renal impairment.

Symptoms

Symptoms can appear within hours to several days after ingestion, depending on the dose and individual factors. The clinical picture is variable and may involve multiple organ systems.

Early (0–24 h)

• Nausea and vomiting – often the first sign.
• Abdominal pain – cramping, sometimes mimicking acute gastritis.
• Diarrhea – watery stools may lead to dehydration.
• Headache – diffuse, can be confused with migraine.
• Generalized weakness or fatigue.

Intermediate (24–72 h)

• Rash – maculopapular, erythematous, or pruritic lesions.
• Fever – may signal early hypersensitivity.
• Elevated serum creatinine – indicating acute kidney injury.
• Metabolic acidosis – due to accumulation of oxypurinol and lactate.
• Hypotension – especially if fluid loss is severe.

Severe / Late (3–7 days)

• Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) – painful blistering, mucosal involvement, skin detachment >10 % of body surface area (TEN).
• Hepatotoxicity – transaminase elevations, jaundice.
• Myelosuppression – leukopenia, thrombocytopenia.
• Seizures or altered mental status – secondary to uremia or severe acidosis.
• Cardiac arrhythmias – from electrolyte disturbances (especially hyper‑kalemia).

Causes and Risk Factors

Overdose may be intentional (suicidal ingestion) or unintentional (dose‑miscalculation, prescribing error, renal dose‑adjustment oversight).

Primary Causes

• Ingestion of >500 mg allopurinol in a single dose (therapeutic range is 100–300 mg/day for most adults).
• Chronic accumulation due to renal failure (oxypurinol, the active metabolite, is renally cleared).
• Concurrent use of drugs that increase oxypurinol levels, e.g., azathioprine, 6‑mercaptopurine, thiazide diuretics.

Risk Factors

• Renal impairment – eGFR <30 mL/min/1.73 m².
• Elderly age – reduced renal clearance and polypharmacy.
• Genetic predisposition – HLA‑B*58:01 allele linked to severe cutaneous reactions.
• Concomitant use of nephrotoxic agents – NSAIDs, ACE inhibitors.
• Alcohol use – potentiates oxidative stress and liver injury.

Diagnosis

Diagnosis relies on a combination of history, physical examination, and targeted laboratory testing.

History & Physical

• Exact dose, timing, and formulation of allopurinol taken.
• Renal and hepatic function baseline.
• Presence of skin lesions, mucosal involvement, or neurologic changes.

Laboratory Tests

• Serum oxypurinol level – not routinely available but definitive when measured.
• Basic metabolic panel – creatinine, BUN, electrolytes, bicarbonate.
• Liver function tests – AST, ALT, alkaline phosphatase, bilirubin.
• Complete blood count – to detect leukopenia or thrombocytopenia.
• Arterial blood gas – for metabolic acidosis.
• Urinalysis – to assess for hematuria or crystalluria indicative of renal injury.

Imaging & Specialized Tests

• Renal ultrasound if obstructive uropathy suspected.
• Skin biopsy for SJS/TEN confirmation (full‑thickness necrosis of epidermis).

Treatment Options

Management is largely supportive, with specific interventions aimed at reducing drug absorption, enhancing elimination, and treating organ dysfunction.

Immediate Measures

• Gastric decontamination – Activated charcoal (50 g) within 1–2 h of ingestion if airway protective reflexes are intact.
• Whole‑bowel irrigation is rarely used but may be considered in massive ingestions.

Enhancing Elimination

• Forced diuresis – Intravenous isotonic saline to maintain urine output >1 mL/kg/h, provided renal function permits.
• Hemodialysis is **not** effective for removing allopurinol itself (small, low‑protein‑binding), but it can clear oxypurinol in severe renal failure.

Supportive Care

• IV fluids for hypotension and to correct metabolic acidosis.
• Electrolyte replacement (especially potassium, bicarbonate).
• Antipyretics (acetaminophen) for fever; avoid NSAIDs due to renal risk.
• Broad‑spectrum antibiotics if secondary infection of skin lesions is suspected.

Treatment of Severe Cutaneous Adverse Reactions

• Immediate discontinuation of allopurinol.
• Transfer to a burn or intensive‑care unit for SJS/TEN.
• Systemic immunomodulators – IVIG (0.4 g/kg/day for 3 days) or cyclosporine (3 mg/kg/day) have shown benefit in observational studies [Mayo Clinic, 2022].
• Wound care with non‑adhesive dressings; ophthalmology consult for ocular involvement.

Renal Support

• Consider renal replacement therapy (hemodialysis or continuous venovenous hemofiltration) for refractory metabolic acidosis, fluid overload, or oliguria.

Medication Adjustments After Recovery

• Alternative urate‑lowering agents – febuxostat (non‑xanthine oxidase inhibitor) or uricosurics, after HLA‑B*58:01 testing if available.
• Low‑dose prophylactic allopurinol may be resumed only under specialist supervision, with dose adjusted to renal function.

Living with Xanthine Oxidase Inhibitor Overdose (Allopurinol Toxicity)

Surviving an overdose often requires long‑term adjustments to prevent recurrence and to manage any residual organ damage.

Medication Management

• Maintain a written medication list; use a pill organizer.
• Never split or combine doses unless instructed.
• For gout prophylaxis, discuss alternative agents with your rheumatologist.

Renal Monitoring

• Check serum creatinine and eGFR every 3–6 months.
• Stay hydrated – aim for at least 2 L of fluid per day unless fluid‑restricted.
• Avoid nephrotoxic over‑the‑counter drugs (NSAIDs, high‑dose vitamin C).

Skin Care

• If a prior SJS/TEN occurred, keep a dermatology follow‑up schedule.
• Use fragrance‑free moisturizers; protect skin from sun exposure.

Lifestyle & Diet

• Limit high‑purine foods (organ meats, anchovies, beer) to reduce uric‑acid burden.
• Maintain a healthy weight; obesity increases gout flares.
• Alcohol moderation – especially beer and spirits.

Psychosocial Support

• If the overdose was intentional, seek mental‑health counseling.
• Support groups for gout or chronic kidney disease can provide peer encouragement.

Prevention

Most overdoses are preventable with proper prescribing practices and patient education.

• Renal dose adjustment – clinicians should calculate the correct dose based on eGFR.
• Medication reconciliation – review all drugs at each visit to avoid duplications.
• Patient education – provide clear verbal and written instructions, emphasizing “do not exceed prescribed dose.”
• Pharmacy safeguards – use blister packs and barcode scanning to catch dosing errors.
• Genetic screening – HLA‑B*58:01 testing before initiating allopurinol in high‑risk ethnic groups (e.g., Han Chinese, Korean, Thai).
• Regular lab monitoring – serum uric acid, creatinine, and liver enzymes every 2–3 months during titration.

Complications

If untreated or delayed, allopurinol toxicity can cause irreversible damage.

• Acute kidney injury – may progress to chronic kidney disease.
• Severe cutaneous adverse reactions – SJS/TEN carry mortality rates of 10–30 %.
• Hepatotoxicity – can lead to acute liver failure.
• Metabolic acidosis – may precipitate cardiac arrhythmias.
• Myelosuppression – increased risk of infection and bleeding.
• Neurologic sequelae – encephalopathy or seizures secondary to uremia.

When to Seek Emergency Care

---

Sources: Mayo Clinic. Allopurinol Side Effects. 2022; CDC. Drug Overdose Prevention. 2023; NIH. Acute Kidney Injury Guideline. 2024; WHO. Severe Cutaneous Adverse Reactions. 2022; Cleveland Clinic. Management of Drug Toxicities. 2023; Peer‑reviewed articles in JAMA Dermatology and Kidney International.